A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EU’s climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.
European Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated the European Biotech Week with an exhibition, Discovering European Biotech Innovation, in the European Parliament in Brussels.
mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer vaccines arising from a new R&D deal with Eli Lilly & Co. Lilly also made an equity investment of €45m.
Belgian Nanobody® producer Ablynx NV said it aims to raise US$175m of its ordinary shares in a global offering, comprised of a public offering of American Depositary Shares ("ADS") in the US and Canada and an offer of ordinary shares in other countries through a private placement.
A complaint against the EMA’s handling of a referral procedure relating to potential side effects of Sanofi/MSD’s HPV vaccine Gardasil and GSK’s HPV jab Cervarix promoted by the Nordic Cochrane Centre and physicians has been rejected by the European Ombudsman.
The European Medicines Agency (EMA) has upgraded Roche’s Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung cancer (NSCLC).
German infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance its clinical programmes with its lead asset IFX-1.
Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients.
Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.